# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

> **NCT06797375** · PHASE1 · COMPLETED · sponsor: **Rallybio** · enrollment: 16 (actual)

## Conditions studied

- Hematologic Diseases
- Autoimmune Diseases

## Interventions

- **DRUG:** RLYB116 for Injection

## Key facts

- **NCT ID:** NCT06797375
- **Lead sponsor:** Rallybio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-14
- **Primary completion:** 2026-02-09
- **Final completion:** 2026-02-23
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06797375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06797375, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06797375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*